In the clinicopathologic analysis, significant factors for PDX engraftment included younger age (OR 0.96, CI 0.92–1.00, p = 0.032), higher Ki-67LI (OR 1.05, CI 1.02–1.07, p < 0.001), NAC status (OR 3.27, CI 1.41–7.60, p = 0.006), larger tumor size (OR 1.20, CI 1.02–1.41, p = 0.029), and histologic grade 3 (OR 4.34, CI 1.08–17.53, p = 0.039). This evidence concerns the gene PSME3 and neoplasm.